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Introduction
Cardiopulmonary bypass induces a systemic inflamma-
tory response syndrome, which leads to activation of the 
complement cascade, oxidative stress and coagulation 
pathways, resulting in endothelial injury and postopera-
tive organ dysfunction following open heart surgery.1,2  
A number of cardiopulmonary bypass circuits with dif-
ferent coatings are available. These systems have been 
shown to provide better hemocompatibility with less 
platelet activation and reduced inflammatory response 
with less white blood cell adhesions. As a result, less post-
operative bleeding and a decreased need of red blood cell 
transfusion3 has been reported. Conflicting results are 
reported with regard to postoperative outcomes follow-
ing the usage of coated perfusion circuits.3,4 The aim of 
this study was to compare the effect of Phisio®- (phos-
phorylcholine), Bioline®- (albumin-heparin) and 
Softline®- (heparin-free, synthetic polymer) coated cir-
cuits on patient outcome after open heart surgery.
Methods
We performed a retrospective database review within a 
randomly picked time period (between January 1st 2010 
and December 31st 2010) and identified a total of 201con-
secutive patients with elective aortic valve replacement, 
on-pump coronary artery bypass graft (CABG) surgery 
or both combined. Patient demographics, operative and 
postoperative data, including 24h levels of c-reactive pro-
tein, white blood cell count, Quick’s test, international 
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normalized ratio (INR), creatinine and follow-up were 
collected and statistically analyzed.
We formed three groups, according to the different 
biocompatible surfaces of the perfusion systems: Group 
1 (Phisio®) used a phosphorylcholine-coated tubing sys-
tem (n=133); Group 2 (Bioline®) used an albumin-hepa-
rin coating (n=32); and Group 3 (Softline®) a synthetic 
polymer coating (n=36).
Perfusion circuits with the following three different 
coatings were used: a phosphorylcholine coating 
(P.h.i.s.i.o.®, Sorin Group, Italy), an albumin-heparin coat-
ing (Bioline®, Maquet Cardiopulmonary AG., Hirrlingen, 
Germany) and a synthetic polymer coating (Softline®, 
Maquet Cardiopulmonary AG). All perfusion tubing sys-
tems were completely coated except for the cannulas. The 
perfusion systems with Phisio® and Bioline® coatings were 
standard systems with a priming volume of 1600ml. The 
Softline®-coated system is a minimized circuit with a 
priming volume of 1200ml. All perfusion systems con-
tained a hard-shell venous reservoir, used a roller pump 
and had an arterial filter. The Phisio® systems used the 
AVANT oxygenator (Sorin, Italy) with which most of 
the patients were treated because of financial reasons. The 
Bioline®- and Softline® systems used a Quadrox-i-Adult or 
a Quadroxy-i Small Adult oxygenator, respectively 
(Maquet Cardiopulmonary AG). The Bioline® systems 
were used for operations which were expected to last long, 
because of their more effective heat exchanger, whereas 
the Sofline® systems were used for patients below a calcu-
lated flow of 5 L/m due to its minimized circuit.
Before cardiopulmonary bypass (CPB) initiation, 
300 IU/kg of heparin was administered intravenously in 
all cases. Re-administration of 5000 IU heparin boluses 
took place if the activated clotting time (ACT) was lower 
than 480 seconds on pump. Either antegrade crystalloid 
Bretschneider or Buckberg blood cardioplegia was used, 
with moderate hypothermia (32-34°C) or normother-
mia. After completion of CPB, heparin was antagonized 
with protamine in a ratio of 1:1.
Statistics: IBM SPSS Statistics 20 (SPSS Inc., Chicago, 
IL, USA) was used for statistical analysis. Continuous 
variables are presented as mean ± standard deviation or 
median with range and compared between groups, using 
the Kruskal-Wallis test. The Chi-square test and Fisher’s 
exact test were used to compare proportions. Kaplan-
Meier curves were used to analyse survival. P-values less 
than 0.05 were considered to be statistically significant.
Results
Baseline characteristics were comparable between the 
groups except for weight, height and hematocrit at admis-
sion, which was lower in Group 3. Those patients were 
meant to be treated with the minimized perfusion system 
and subsequent reduced priming volume. Accordingly, 
there were more women in that group (<0.005) (see 
Table 1).
Operative characteristics are shown in Table 2. Time 
of surgery, CPB and cross-clamp time, type of surgery 
and lowest temperature were comparable between the 
groups.
Table 3 shows the blood results on day one after sur-
gery. C-reactive protein, white blood cell count, Quick’s 
test, INR and creatinine were analyzed. Except for a lower 
creatinine in Group 3, there were no further significant 
differences.
Overall in-hospital mortality and stroke rate was 1.5% 
(n=3) for each. They all occurred in Group 1 (Phisio®). 
Chest tube drainage, re-exploration for bleeding, red 
blood cell transfusion, infection, new onset dialysis, 
postoperative myocardial infarction, ventilation time, 
ICU stay and hospital stay were comparable between the 
groups without significant differences.
Median follow-up time was 180 days (32-540 days). 
Three patients died during follow-up, all in Group 1 
(Phisio®). The overall 30-day and 1-year late survivals 
were 98.5% and 96.7±1.9%, respectively, without signifi-
cant difference between the groups (95.2 ± 2.7% for 
Group 1 and 100% for Groups 2 and 3).
Discussion
When heparin was first used in medical devices, it was 
known to have anti-thrombotic effects.5 Later, it was proven 
to have biocompatibility properties as well by inhibiting 
contact and complement activation and adsorbing lipo-
proteins, simulating the behaviour of cell membranes.6,7
Many trials show that heparin-coated circuits reduce 
postoperative blood loss and the need for red blood cell 
transfusion,3 and ventilation time and ICU stay.8
One meta-analysis with 3434 patients in 41 original 
randomized papers shows that heparin-coated circuits 
decrease blood loss and red blood cell transfusion by 
20%, re-sternotomy by 40%, ventilation by 78 minutes, 
average ICU stay by 9.3 hours and hospital stay by 0.5 
days when compared to non-heparin-bonded circuits. 
There was also a significant difference in favour of the 
heparin-coated system regarding death, new onset myo-
cardial infarction, stroke, wound infection and atrial 
fibrillation.9
Sohn et al.10 showed, in a randomized trial with 73 
CABG patients, that heparin-coated and phosphoryl-
choline-coated circuits induce less inflammatory 
responses and oxidative stress compared to other cir-
cuits. Clinical outcome was not investigated.
Thiara et al.11 described a comparable degree of in 
vivo biocompatibility and less inflammatory response 
in Phisio®- and Bioline®-coated circuits by analyzing 
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various inflammatory markers. These findings might 
explain our results, which did not show differences in 
outcome comparing Phisio®- and Bioline®-coated cir-
cuits either.
Tayama et al.12 were able to show, in a randomized 
trial of 27 CABG patients, that Bioline® circuits reduce the 
inflammatory responses when compared to non-heparin 
coated circuits, although this effect did not appear to 
have any clinical impact. These findings correlate well 
with ours.
The beneficial effect of heparin-coating might be due 
to a reduced systemic heparinization, resulting in 
reduced blood loss and adverse events.13,14 There is one 
randomized trial with 90 patients showing better post-
operative outcomes with reduced ventilation times and 
haemorrhage in high-risk groups (Euroscore +6), using 
hyaluronan-based heparin-bonded circuits.15
It is possible that, in an elective series like ours with 
routine aortic valve and CABG patients with short CPB 
and cross-clamp times, there is no evidence of significant 
Table 1. Baseline characteristics
Group 1 Group 2 Group 3 P
 Phisio® Bioline® Softline®  
 N=133 N=32 N=36  
Age (years) 68±11 67±10 68±13 0.6
EuroSCORE 5.7±2.7 5.3±2.3 6.5±2.8 0.2
Male patients 88 (66.1%) 27 (84.3%) 12 (33.3%) 0.005
Weight (kilograms) 82±15 86±13 63±10 0.005
Height (centimetres) 168±9 169±9 160±8 0.005
Congestive heart failure 11 (8.2%) 6 (18.7%) 4 (11.1%) 0.2
CCS III/IV 30 (22.5%) 10 (31.2%) 8 (22.2%) 0.6
NYHA III/IV 42 (31.5%) 8 (25%) 13 (36.1%) 0.6
Previous myocardial infarction 8 (6%) 4 (12.5%) 2 (5.5%) 0.4
Smoking history 65 (48.8%) 22 (68.7%) 21 (58.3%) 0.1
Diabetes mellitus 33 (24.8%) 7 (21.8%) 5 (13.8%) 0.4
- oral therapy 22 (16.5%) 5 (15.6%) 3 (8.3%) 0.5
- insulin 11 (8.2%) 2 (6.2%) 2 (5.5%) 0.9
Hypertension 97 (72.9%) 23 (71.8%) 22 (61.1%) 0.3
Hypercholesterolaemia 85 (63.9%) 21 (65.6%) 16 (44.4%) 0.08
Creatinine>200micromol/L 4 (3%)  0 1 (2.7%) 1
COPD 19 (14.2%) 3 (9.3%) 4 (11.1%) 0.8
Extracardiac-arteriopathy 15 (11.2%) 6 (18.7%) 4 (11.1%) 0.5
Cerebrovascular disease 5 (3.7%) 3 (9.3%)  0 0.1
Atrial fibrillation 11 (8.2%) 2 (6.2%) 1 (1.7%) 0.5
Haematocrit % 40 (27-48) 41 (35-50) 37 (27-45) 0.005
CCS: Canadian Cardiovascular Society Angina Class; NYHA: New York Heart Association; COPD: chronic obstructive pulmonary disease
Table 2. Operative characteristics
Group 1 Group 2 Group 3 P
 Phisio® Bioline® Softline®  
N=133 N=32 N=36  
Aortic valve replacement 65 (48.9%) 15 (46.9%) 20 (55.6%) 0.6
CABG 40 (30%) 10 (31.3%) 8 (22.2%) 0.6
CABG + Aortic valve 28 (21.1%) 7 (21.8%) 8 (22.2%) 1
Post-op IABP 6 (4.5%)  0 1 (2.7%) 0.7
CPB time (min) 107 (31-330) 110 (58-207) 96 (57-238) 0.6
Cross-clamp (min) 64 (0-142) 74 (0-155) 69 (0-156) 0.2
Time of surgery (min) 210 (115-550) 219 (115-462) 220 (117-449) 0.6
Temperature (°C) 34 (30-37) 34 (32-37) 34 (32-37) 0.9
CABG: coronary artery bypass grafting; IABP: intra aortic balloon pump; CPB: cardiopulmonary bypass
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difference in clinical outcome after using Phisio®, 
Bioline® or Softline® circuits. Therefore, further analysis 
of high-risk groups (i.e. high Euroscore, emergency pro-
cedures, etc.) might reveal clinical and economic advan-
tages that ease decision making for the future.
The limitations of our study are as follows. It is not a 
controlled study, but an outcome analysis. It is retrospec-
tive observational and, therefore, open to selection bias, 
which may have contributed to the lack of significant dif-
ferences in outcome (the Softline® group differs from the 
others, which is explainable by their smaller body size 
that required the use of this circuit in the first place). 
Furthermore, the study is not blinded and, therefore, 
open to treatment bias, which may also have affected 
the outcome (not just the coatings are different, but also 
the circuits and the priming volumes). Due to the multi-
ple outcomes, there is the risk of type I statistical error. 
However, it was our intention to analyze multiple out-
comes in order to be able to find any profound differ-
ences. No sample size estimation was performed because, 
in the case of post-hoc analysis, it would go far beyond 
the limits of this paper.
Conclusion
Our findings suggest that in-hospital and follow-up out-
comes are comparable in elective isolated aortic valve, 
CABG or both combined open heart surgery patients 
after using either phosphorylcholine-, heparin-albumin- 
or synthetic polymer-coated circuits during cardiopul-
monary bypass. Further analysis of the data is required 
(cost-benefit of the different circuits, especially in high-
risk patients) in order to ease decision making in the 
future.
Table 3. Laboratory work 24 hours after surgery
Group 1 Group 2 Group 3 P
 Phisio® Bioline® Softline®  
 N=133 N=32 N=36  
C-reactive protein (ng/l) 54 (8-251) 50 (2-109) 62 (13-211) 0.7
WBC (G/l) 11 (4-25) 10 (6-19) 9 (4-20) 0.1
Quick’s test (%) 75 (5.2-123) 75 (40-120) 73 (40-125) 0.8
INR 1.2 (1-1.6) 1.2 (1-1.7) 1.2 (1-1.7) 0.9
Creatinine micromol/L 89 (43-222) 85 (64-188) 78 (39-195) 0.01
WBC: white blood count; INR: international normalized ratio
Table 4. In-hospital outcomes
Group 1 Group 2 Group 3 P
 Phisio® Bioline® Softline®  
N=133 N=32 N=36  
Mortality 3 (2.2%)   0   0 1
Stroke 3 (2.2%)   0   0 1
Ventilation time (hours) 11 (0-1307) 9 (0-550) 11 (0-217) 0.2
Re-thoracotomy 11 (8.3%) 1 (3.1%)   0 0.1
ICU stay (hours) 23 (0-1961) 24 (0-550) 27 (15-405) 0.06
Hospital stay (days) 9.5 (1-89) 9 (3-29) 10.5 (1-36) 0.4
Drainage (l) (during ICU stay) 0.6 (0.03-8) 0.6 (0.1-5.4) 0.6 (0.08-4) 0.4
RBC (unit until end of ICU stay) 2.2 (0-61) 1.5 (0-19) 2.2 (0-9) 0.9
Myocardial infarction 2 (1.5%)   0 1 (2.7%) 0.7
Dialysis 10 (7.5%) 1 (3.1%) 1 (2.7%) 0.5
Multi-system failure 2 (1.5%) 1 (3.1%)   0 0.4
Pneumonia 12 (9%) 1 (3.1%) 1 (2.7%) 0.3
ARDS 1 (0.7%) 1 (3.1%)   0 0.3
Sepsis 7 (5.2%) 1 (3.1%) 1 (2.7%) 1
ICU: intensive care unit; RBC: red blood cell transfusion;  ARDS: acute respiratory distress syndrome
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